Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  MIA is a potential biomarker for tumour load in neurofibromatosis type 1

Kolanczyk, M., Mautner, V., Kossler, N., Nguyen, R., Kuhnisch, J., Zemojtel, T., et al. (2011). MIA is a potential biomarker for tumour load in neurofibromatosis type 1. BMC Med, 9, 82. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21726432 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224593/pdf/1741-7015-9-82.pdf?tool=pmcentrez.

Item is

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Kolanczyk, M.1, Autor           
Mautner, V., Autor
Kossler, N.1, Autor           
Nguyen, R., Autor
Kuhnisch, J., Autor
Zemojtel, T.2, Autor           
Jamsheer, A., Autor
Wegener, E., Autor
Thurisch, B., Autor
Tinschert, S.1, Autor           
Holtkamp, N., Autor
Park, S. J., Autor
Birch, P., Autor
Kendler, D., Autor
Harder, A., Autor
Mundlos, S.1, Autor           
Kluwe, L., Autor
Affiliations:
1Research Group Development & Disease (Head: Stefan Mundlos), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1433557              
2Dept. of Computational Molecular Biology (Head: Martin Vingron), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1433547              

Inhalt

einblenden:
ausblenden:
Schlagwörter: Adolescent; Adult; Aged; Animals; Disease Models, Animal; Extracellular Matrix Proteins/*analysis; Female; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplasm Proteins/*analysis; Neurofibromatosis 1/*pathology; *Tumor Burden; Tumor Markers, Biological/*analysis; Young Adult
 Zusammenfassung: BACKGROUND: Neurofibromatosis type 1 (NF1) is a frequent genetic disease characterized by multiple benign tumours with increased risk for malignancy. There is currently no biomarker for tumour load in NF1 patients. METHODS: In situ hybridization and quantitative real-time polymerase reaction were applied to investigate expression of cartilage-specific genes in mice bearing conditional inactivation of NF1 in the developing limbs. These mice do not develop tumours but recapitulate aspects of NF1 bone dysplasia, including deregulation of cartilage differentiation. It has been recently shown that NF1 tumours require for their growth the master regulator of cartilage differentiation SOX9. We thus hypothesized that some of the cartilage-specific genes deregulated in an Nf1Prx1 mouse model might prove to be relevant biomarkers of NF1 tumours. We tested this hypothesis by analyzing expression of the SOX9 target gene product melanoma-inhibitory activity/cd-rap (MIA) in tumour and serum samples of NF1 patients. RESULTS: Increased expression of Mia was found in Nf1-deficient cartilage in mice. In humans, MIA was expressed in all NF1-related tumours and its serum levels were significantly higher in NF1 patients than in healthy controls. Among NF1 patients, MIA serum levels were significantly higher in those with plexiform neurofibromas and in those with large number of cutaneous (> 1,000) or subcutaneous (> 100) neurofibromas than in patients without such tumours. Most notably, MIA serum levels correlated significantly with internal tumour burden. CONCLUSIONS: MIA is a potential serum biomarker of tumour load in NF1 patients which could be useful in following the disease course and monitoring the efficacy of therapies.

Details

einblenden:
ausblenden:
Sprache(n):
 Datum: 2011
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: BMC Med
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: -
Seiten: - Band / Heft: 9 Artikelnummer: - Start- / Endseite: 82 Identifikator: ISSN: 1741-7015 (Electronic) 1741-7015 (Linking)